Topical Finasteride vs Oral: The Questions Men Actually Ask
Topical finasteride exists to chase a specific hope: the follicle-level DHT reduction of the oral tablet with less of the drug circulating through the body. Published work supports meaningfully lower systemic exposure. It does not support calling the topical side-effect-free, and the FDA said so directly in 2025. The full picture, including the questions about partners and pregnancy.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 10 min read
Key facts
Finasteride blocks 5-alpha-reductase, reducing conversion of testosterone to DHT, the androgen most implicated in male pattern hair loss. The oral 1 mg tablet is FDA-approved as Propecia® and generics.
Topical finasteride is a compounded, non-FDA-approved format; published studies report substantially lower blood finasteride levels and similar scalp DHT reduction compared with the tablet, in study conditions.
In April 2025 the FDA issued an alert citing adverse event reports, including sexual and psychiatric effects, in men using compounded topical finasteride: lower systemic exposure is not zero exposure.
Finasteride in any form is hazardous to a developing male fetus; pregnant women should not handle crushed tablets, and topical users must prevent transfer from application sites.
Stopping finasteride, in any format, returns DHT and the hair-loss trajectory toward baseline over subsequent months.
What does finasteride actually do?
Male pattern hair loss runs substantially on dihydrotestosterone, DHT, an androgen converted from testosterone by the enzyme 5-alpha-reductase. In genetically susceptible follicles, DHT progressively miniaturizes the hair. Finasteride inhibits the type II form of that enzyme, lowering DHT in scalp and serum, which is the entire mechanism: less DHT pressure on susceptible follicles. The oral 1 mg tablet has decades of use and a large trial record behind its approval as Propecia® and its generics.
Because the mechanism is hormonal and systemic when taken as a tablet, the drug's side effect conversation has always centered on sexual effects in a minority of users, and, more contested, reports of persistent symptoms after stopping. That background is what created the demand for a topical version in the first place.
Does topical finasteride actually keep the drug out of your bloodstream?
Partially, and the quantities matter. Published pharmacokinetic work comparing a topical finasteride solution with the oral tablet reports blood finasteride exposure lower by an order of magnitude with the topical, while scalp DHT suppression remained in a similar range, which is the finding the whole category rests on. Lower is the accurate word; zero is not. Finasteride absorbed through the scalp still enters circulation and still lowers serum DHT measurably.
Formulation drives everything here: concentration, vehicle, dose volume, and frequency vary across compounded products, and systemic absorption varies with them. That variability is intrinsic to a compounded category with no single approved formulation, and it is why prescriber oversight and a consistent, named pharmacy product matter more here than in most topicals.
What did the FDA's 2025 alert actually say?
In April 2025 the FDA published a safety communication about compounded topical finasteride, citing adverse event reports collected over several years that included sexual dysfunction, mood changes, and other effects mirroring the oral tablet's known profile, in men who often believed a topical could not cause them. The agency's core points: these products are not FDA-approved, patients were often unaware systemic absorption occurs, and prescribers should counsel accordingly.
Read plainly, the alert is not a finding that topical finasteride is more dangerous than the tablet; it is a correction to the marketing-borne belief that it is risk-free. A platform that sells topical finasteride while presenting that alert to you unprompted is behaving the way the agency asked; a platform that buries it is answering a different question about itself.
3/mo CHROMA23+ Membership, medication priced separately, every cost shown first.
Can my partner be exposed from my scalp, pillow, or hands?
The reason this question matters so much: finasteride can harm the genital development of a male fetus, which is why pregnant women are warned against handling broken tablets. For topical users the exposure routes are practical ones, wet product transferred by hands, scalp contact before drying, shared pillows immediately after application. The published transfer data is thin, so guidance is built from prudence: apply precisely, wash hands thoroughly, allow full drying time before contact or bed, and time applications away from close contact.
For couples who are pregnant or trying to conceive, raise the topic explicitly with the prescribing physician rather than engineering private workarounds. Sometimes the right clinical answer during that season is a different treatment plan entirely, and a physician can say so.
How do topical and oral compare on the things men actually weigh?
On evidence: the tablet holds the approval and the deep trial record; the topical holds smaller published studies and the pharmacokinetic case above, plus real-world use at scale through telehealth. On side effect likelihood: lower systemic exposure reasonably predicts lower systemic risk, and the FDA alert stands as the reminder that lower is not none. On routine: a daily tablet versus a daily scalp application with drying time, which sounds trivial until adherence decides outcomes. On combination: topical finasteride is frequently compounded together with minoxidil in one solution, one application covering both mechanisms, which for many men is the format's strongest practical argument; the minoxidil half of that story is covered in our women's minoxidil guide and applies broadly.
On switching: men moving from oral to topical, or the reverse, are adjusting systemic exposure of the same molecule, and the transition question, including what happens to gains, belongs to the prescriber armed with your history rather than to a rule of thumb.
What should I expect in the first months, and what if I stop?
Expect the same cycle physics as every follicle-level treatment: an early period where a temporary shedding uptick is possible and recognized, assessment over months with consistent photos rather than weekly mirror verdicts, and a maintenance relationship thereafter. Stopping, in either format, removes the DHT suppression, and over subsequent months the follicles resume their prior trajectory; treatment-attributable hair is gradually lost back. Neither format is a course you complete; both are ongoing decisions.
And the gate before all of it: confirming that your loss is actually androgenetic. Diffuse, sudden, or patchy loss has a different differential, and finasteride aimed at the wrong diagnosis is months of nothing. An evaluation first is not ceremony; it is aim.
Frequently asked questions
Is topical finasteride FDA-approved?
No. It is a compounded prescription format from state-licensed pharmacies; the FDA-approved finasteride products for hair loss are the oral 1 mg tablet, Propecia® and generics. The standard compounded-product disclosure applies, and the 2025 FDA alert makes clear the agency watches this category specifically.
Will topical finasteride lower my libido like the tablet stories say?
The documented rates for the oral tablet put sexual side effects in a minority of users, and the topical's lower systemic exposure reasonably lowers, without eliminating, that likelihood; the FDA alert exists because such reports occurred with topicals too. Any such effect is a report-to-your-physician event, not something to ride out silently.
Can women use topical finasteride?
Finasteride is not used by women who are or may become pregnant, full stop, and its role in other women is a specialist decision with a different evidence base than the male one. Women's first-line topical territory belongs to minoxidil, covered in our companion guide.
Does donating blood matter on finasteride?
Yes: donors on finasteride are deferred for a period after the last dose, because donated blood could reach a pregnant recipient. The deferral applies regardless of why you take it, and blood centers publish their current rules.
About CHROMA23®
CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.